

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad - 500 034. Telangana, India.

Tel: 040 30211600 / 23551081 Fax: 040 30211602 Email: neuland@neulandlabs.com www.neulandlabs.com

November 7, 2016

To B S E Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001 To
The National Stock Exchange of
India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB

Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of un-audited financial results for the quarter ended September 30, 2016, published in Financial Express and Andhra Prabha on November 5, 2016 for your reference.

Thanking you,

Yours faithfully, For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

Encl: as above

NEULAND LABORATORIES LIMITED (CIN: L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2016 (PROVISION SI. Quarter Quarter Quarter Quarter Half Year							
No		Ended	Ended	Quarter	Half Year Ended	Half Year Ended	Year
	Particulars		30-06-2016	30-09-2015	30-09-2016	30.00.2015	Ended 31-03-201
1	MARINE TO THE PARTY OF THE PART	(Unaudited	(Unaudited)	(Unaudited)	(Unaudited	(Unaudited)	(Audited
1	Income from operations			(Criadantea)	Conducted	(Oridudited)	(Addited
	(a)Net Sales / Income from Operations(net of excise duty)	14,442.89	14,558.44	12,404.40	29,001.33	24 244 00	40 574 7
	(b)Other Operating Income	515.98	418.16	413.89	934.14	24,316.88 873.39	48,576.7
	Total Income from Operations (Net)	14,958.87	14,976.60		29,935.47	25 100 27	2,420.3
2	Expenses	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	. 1,770.00	12,010.27	27,733.47	23,170.27	30,997.0
	(a)Cost of Materials consumed	6,871.67	6,970.72	6,697.14	13,842.39	13,397.53	25,956.6
	(b) Changes in inventories of finished goods and work-in-progress	633.99	79.14	108.75	713.13	(266.60)	(611.18
	(c) Employee benefits expense	1,559.22	1,666.16	1,454.95	3,225.38	2,982.59	5,989.2
	(d)Depreciation and amortisation expense	454.42	436.07	389.59	890.49	769.79	1,574.20
000	(e)Manufacturing expenses	1,584.83	1,462.10	1,177.99	3,046.93	2,403.69	5,284.20
1	(f)Sales promotion expenses including sales commission	714.32	1,512.20	262.70	2,226.52	413.87	2,039.90
	(g) Other expenses Total expenses	1,073.49	830.05	1,164.85	1,903.54	2,196.69	4,351.22
3	Profit from energians before the	12,891.94	12,956.44	11,255.97	25,848.38		44,584.30
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,066.93	2,020.16	1,562.32	4,087.09	3,292.71	6,412.7
4	Other Income						
5	Profit from ordinary activities before finance costs and	(5.54)	48.70	(2.29)	43.16	50.57	161.91
	exceptional items (3+4)	2,061.39	2,068.86	1,560.03	4,130.25	3,343.28	6,574.62
6	Finance Costs	F22 42	100.10			Total was	
7	Profit from ordinary activities after finance costs but before	522.42 1,538.97	609.68	627.79	1,132.10	1,281.89	2,446.60
	exceptional items (5-6)	1,338.97	1,459.18	932.24	2,998.15	2,061.39	4,128.02
8	Exceptional Items						
9	Profit from ordinary activities before tax (7-8)	1,538,97	1,459.18	932.24	2,998.15	2 044 20	
	Tax expense	500.10	488.05	311.83	988.15	2,061.39	4,128.02
11	Net profit from ordinary activities after tax (9-10)	1,038.87	971.13	620.41	2,010.00	710.92	1,486.54
12	Extraordinary items	.,000.07	771.13	020.41	2,010.00	1,330.47	2,641.48
13	Net profit for the period (11-12)	1,038.87	971.13	620.41	2,010.00	1,350.47	2,641,48
14	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.39	895.39	895.39	895.39	895.39	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of			Name of the last	0,0.07	0/3.3/	073.37
	previous accounting year				in the same	Press press	17,437,92
10.1	Earnings per share (before extraordinary items)(of ₹10 each)		-	-	-		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3-1	(In absolute)	324			approduction (co.	1,51) Suppor	
Bart	(a)Basic (not annualized) (b)Diluted (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
16 11	Farnings per share (after extraordine it was to fine	11.69	10.93	6.98	22.62	15.20	29.73
IOI	Earnings per share (after extraordinary items)(of ₹10 each) (In absolute ₹)	CONTRACTOR OF THE PARTY OF THE					
1	(a)Basic (not annualized)		Windship Hall		STATE OF THE PARTY OF	The galling	
	(b)Diluted (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
1	See accompanying notes to the financial results	11.69	10.93	6.98	22.62	15,20	29.73
300	accompanying notes to the infancial results	1	A Toponia Company	and the latest terms of th	and the same of the same of		

1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on November 3, 2016, and approved and taken on record at the Board of Directors meeting held on November 4, 2016.

- 2 EPS for quarters are not annualized.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard AS 17 "Segment Reporting".
- 4 The above unaudited financial results have been reviewed by the statutory auditors of the Company pursuant to regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- 5 The board has accorded its approval for the Scheme of Amalgamation and Arrangement amongst the Company, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NPRPL") and their respective shareholders and creditors. As a part of the proposed transaction, both NHSPL and NPRPL will be amalgamating into the Company and consequently, new equity shares of the Company would be issued to the shareholders of NHSPL and NPRPL.
- 6 The Company has entered into a Joint Development Agreement(JDA) with Phoenix Embassy techno Zone Private Limited for development of the land owned by the Company at Nanakramguda, Hyderabad. In terms of the said JDA, the Company would be entitled to receive approximately 23% share of the saleable area of the proposed project, which would be duly determined on the basis of an approval of the building plans by the authorities concerned.
- 7 The statement of assets and liabilities is as follows:

-	-		1000		
1				Amount	in ₹ Lacs
	SI. No.	THE PROPERTY AND ADDRESS OF THE PARTY OF THE		As on -09-2016 naudited)	As on 31-03-2016 (Audited)
	A	EQUITY AND LIABILITIES			
	1	Shareholders' Funds	elinia cas	10016	an multiple of the
-		(a) Share Capital	-	895.39	895.39
	10 4	(b) Reserves and Surplus	19	,531.81	17,521.81
7			20	,427.20	18,417.20
-	2	Share Application Money Pending Allotn Non-current Liabilities	nent	7 (881%)	ellorites -
	H HA	(a) Long-term Borrowings	4	,769.43	4,540.00
	To loo	(b) Deferred Tax Liability (Net)	1	,421.10	1,422.82
		(c) Other Long-term Liabilities	District on	253.00	253.00
		(d) Long-term Provisions		714.44	684.92
	.	SVENNER ROLL	7	157.97	6,900.74
	4	Current Liabilities	-	-	
		(a) Short-term Borrowings		938.90	12,362.90
		(b) Trade Payables		127.39	8,332.28
		(c) Other Current Liabilities (d) Short-term Provisions	5,	511.26	5,774.29
-		(d) Short-term Provisions	20	510.83	546.72
	55	TOTAL		088.38	27,016.19
	В	ASSETS	55,0	673.55	52,334.13
1	1	Non-current Assets			PATRICIA CONTRACTOR
1		(a) Fixed Assets	10	903.36	47 075 00
		(b) Non-current Investments		754.58	17,925.09 754.58
		(c) Long-term Loans and Advances		309.94	2,320.67
	1000	(-) cours and Advances		967.88	21,000.34
	2	Current Assets	21,	707.00	21,000.34
		(a) Inventories	12	081.80	12,666.29
		(b) Trade Receivables		528.10	11,910.83
	5	(c) Cash and Bank Balances		355.63	904.02
		(d) Short-term Loans and Advances		692.87	4,959.00
	5	(e) Other Current Assets		047.27	893.65
1	1			705.67	31,333.79
L		TOTAL			52,334.13
8	Pre	vious period figures have been re-	- International	THE R. P. LEWIS CO., LANSING, Married World	

grouped/reclassified wherever necessary, to confirm to the current period's classification.

> By Order of the Board For Neuland Laboratories Limited

Place: Hyderabad Date: November 04, 2016

Dr. D.R.Rao Chairman & Managing Director (DIN 00107737)



NEULAND LABORATORIES LIMITED

(CIN: L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



SI. No.	Particulars	Quarter Ended 30-09-2016 (Unaudited)	Quarter Ended 30-06-2016 (Unaudited)	Quarter Ended 30-09-2015 (Unaudited)	Half Year Ended 30-09-2016 (Unaudited	Half Year Ended 30-09-2015 (Unaudited)	Year Ended 31-03-2016 (Audited)
1	Income from operations	4444000	44.550.44	42 404 40	20 004 22	24 244 00	48,576.71
	(a)Net Sales / Income from Operations(net of excise duty)	14,442.89	14,558.44	413.89	29,001.33	873.39	2,420.30
	(b)Other Operating Income	515.98 14.958.87	418.16		29,935.47		50,997.01
	Total Income from Operations (Net)	14,930.07	14,970.00	12,010.27	27,733.47	23,170.21	30,777.01
	Expenses (a)Cost of Materials consumed	6,871.67	6,970.72	6,697.14	13,842.39	13,397.53	25,956.67
	(b) Changes in inventories of finished goods and work-in-progress	633.99	79.14		713.13	(266.60)	(611,18)
	(c) Employee benefits expense	1,559.22	1,666.16		3,225.38	2,982.59	5,989.23
	(d)Depreciation and amortisation expense	454.42	436.07		890.49	769.79	1,574,26
	(e)Manufacturing expenses	1,584.83	1,462.10	1,177.99	3,046.93	2,403.69	5,284.20
	(f)Sales promotion expenses including sales commission	714.32	1,512.20	262.70	2,226.52	413.87	2,039.90
	(g) Other expenses	1,073.49	830.05		1,903.54	2,196.69	4,351.22
	Total expenses	12,891.94	12,956.44				
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,066.93	2,020.16	777 785	4,087.09	3,292.71	6,412.71
	Other Income	(5.54)	48.70		43.16	50.57	161.91
	Profit from ordinary activities before finance costs and exceptional items (3+4)	2,061.39	2,068.86		4,130.25	3,343.28	6,574.62
6	Finance Costs	522.42	609.68		1,132.10	1,281.89	2,446.60
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,538.97	1,459.18	932.24	2,998.15	2,061.39	4,128.02
8	Exceptional Items	100		33	. A		4 400 00
	Profit from ordinary activities before tax (7-8)	1,538.97	1,459.18		2,998.15	2,061.39	4,128.02
10	Tax expense	500.10	488.05		988.15	710.92	1,486.54
11	Net profit from ordinary activities after tax (9-10)	1,038.87	971.13	620.41	2,010.00	1,350.47	2,641.48
	Extraordinary items	4 000 00	074 47	(20 44	2 040 00	1,350.47	2,641.48
13	Net profit for the period (11-12)	1,038.87	971.13 895.39		2,010.00 895.39	895.39	895.39
14	Paid-up Equity Share Capital (Face value of ₹10 per share)	693.39	093.39	073.37	673.37	073.37	073.37
15	Reserves excluding Revaluation Reserve as per balance sheet of	CONTRACT CO.		Line Some	Contract All	San Blead	17,437.92
16.i	previous accounting year Earnings per share (before extraordinary items)(of ₹10 each)				- Take 017	Curio no	a Li Chre
	(In absolute)	11.69	10.93	6.98	22.62	15.20	29.73
	(a)Basic (not annualized) (b)Diluted (not annualized)	11.69	10.93			15.20	29.73
16.11	(a) the control (for annualized) Earnings per share (after extraordinary items)(of ₹10 each) (In absolute ₹)	11.07	10.73	0.70			
	(a)Basic (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
	(b)Diluted (not annualized)	11.69	10.93			15.20	29.73
	See accompanying notes to the financial results		THE PERSON NAMED IN	ALTON THO	BURNE THE		MENESS.

NOTES:

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on November 3, 2016, and approved and taken on record at the Board of Directors meeting held on November 4, 2016.
- 2 EPS for quarters are not annualized.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- 4 The above unaudited financial results have been reviewed by the statutory auditors of the Company pursuant to regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- 5 The board has accorded its approval for the Scheme of Amalgamation and Arrangement amongst the Company, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NHRPL") and their respective shareholders and creditors. As a part of the proposed transaction, both NHSPL and NPRPL will be amalgamating into the Company and consequently, new equity shares of the Company would be issued to the shareholders of NHSPL and NPRPL.
- 6 The Company has entered into a Joint Development Agreement(JDA) with Phoenix Embassy techno Zone Private Limited for development of the land owned by the Company at Nanakramguda, Hyderabad. In terms of the said JDA, the Company would be entitled to receive approximately 23% share of the saleable area of the proposed project, which would be duly determined on the basis of an approval of the building plans by the authorities concerned.
- 7 The statement of assets and liabilities is as follows:

		Amount in ₹ Lacs				
SI.	Particulars	As on 30-09-2016 (Unaudited)	As on 31-03-2016 (Audited)			
4	EQUITY AND LIABILITIES	T 100 000				
	Shareholders' Funds	The state of the s				
	(a) Share Capital	895.39	895.39			
9	(b) Reserves and Surplus	19,531.81	17,521.81			
-		20,427.20	18,417.20			
2	Share Application Money Pending Allotment					
3	Non-current Liabilities	arr-submap				
	(a) Long-term Borrowings	4,769.43	4,540.00			
	(b) Deferred Tax Liability (Net)	1,421.10	1,422.82			
	(c) Other Long-term Liabilities	253.00	253.00			
	(d) Long-term Provisions	714.44	684.92			
		7,157.97	6,900.74			
4	Current Liabilities	100000000000000000000000000000000000000				
	(a) Short-term Borrowings	11,938.90	12,362.90			
	(b) Trade Payables	10,127.39	8,332.28			
200	(c) Other Current Liabilities	5,511.26	5,774.29			
	(d) Short-term Provisions	510.83	546.72			
3-1		28,088.38	27,016.19			
	TOTAL	55,673.55	52,334.13			
В	ASSETS	100000000000000000000000000000000000000				
1	Non-current Assets					
	(a) Fixed Assets	18,903.36	17,925.09			
	(b) Non-current Investments	754.58	754.58			
	(c) Long-term Loans and Advances	2,309.94	2,320.67			
-		21,967.88	21,000.34			
2	Current Assets	de a la ba				
N	(a) Inventories	12,081.80	12,666.29			
	(b) Trade Receivables	15,528.10	11,910.83			
-2	(c) Cash and Bank Balances	1,355.63	904.02			
	(d) Short-term Loans and Advances	3,692.87	4,959.00			
	(e) Other Current Assets	1,047.27	893.65			
		33,705.67	31,333.79			
	TOTAL	55,673.55	52,334.13			

8 Previous period figures have been re-grouped/reclassified wherever necessary, to confirm to the current period's classification.

> By Order of the Board For Neuland Laboratories Limited

Sd/-Dr. D.R.Rao Chairman & Managing Director (DIN 00107737)

Place: Hyderabad Date: November 04, 2016